PURPOSE: To assess the prognostic value of the Mandard tumour regression score (TRG) following pre-operative chemo/radiotherapy in patients with locally advanced rectal cancer. METHODS AND MATERIALS: The study involved 158 patients with locally advanced rectal cancer treated with pre-operative long course chemo/radiotherapy at Nottingham University Hospital between April 2001 and December 2008. Patients were treated with radiotherapy to a dose of 50 Gy in 25 fractions over 5 weeks with or without concurrent capecitabine chemotherapy at a dose of 1650 mg/m(2)/day. Surgery was normally performed after an interval of 6-10 weeks. The response to pre-operative treatment was carefully graded by a single pathologist using the five point Mandard score. The median follow-up was 40 months (range 3-90 months). RESULTS: Of the 158 patients 14% were TRG1, 41% were TRG2, 31% were TRG3, 13% were TRG4 and 1% were TRG5. The groups were combined into TRG1, TRG2 and TRG3-5 to simplify further analysis. The Mandard score was clearly related to both disease-free (p < 0.001) and overall survival (p = 0.012). On multivariate analysis perineural invasion, nodal status, TRG and circumferential resection margin status were the most powerful predictors of disease-free survival. CONCLUSIONS: The Mandard tumour regression score is an independent prognostic factor and predicts for long-term outcome following pre-operative chemo/radiotherapy in rectal cancer.
PURPOSE: To assess the prognostic value of the Mandard tumour regression score (TRG) following pre-operative chemo/radiotherapy in patients with locally advanced rectal cancer. METHODS AND MATERIALS: The study involved 158 patients with locally advanced rectal cancer treated with pre-operative long course chemo/radiotherapy at Nottingham University Hospital between April 2001 and December 2008. Patients were treated with radiotherapy to a dose of 50 Gy in 25 fractions over 5 weeks with or without concurrent capecitabine chemotherapy at a dose of 1650 mg/m(2)/day. Surgery was normally performed after an interval of 6-10 weeks. The response to pre-operative treatment was carefully graded by a single pathologist using the five point Mandard score. The median follow-up was 40 months (range 3-90 months). RESULTS: Of the 158 patients 14% were TRG1, 41% were TRG2, 31% were TRG3, 13% were TRG4 and 1% were TRG5. The groups were combined into TRG1, TRG2 and TRG3-5 to simplify further analysis. The Mandard score was clearly related to both disease-free (p < 0.001) and overall survival (p = 0.012). On multivariate analysis perineural invasion, nodal status, TRG and circumferential resection margin status were the most powerful predictors of disease-free survival. CONCLUSIONS: The Mandard tumour regression score is an independent prognostic factor and predicts for long-term outcome following pre-operative chemo/radiotherapy in rectal cancer.
Authors: Robert Farkas; Eva Pozsgai; Andrew V Schally; Andras Szigeti; Edit Szigeti; Zoltan Laszlo; Andras Papp; Eva Gomori; Laszlo Mangel; Peter O Horvath; Szabolcs Bellyei Journal: J Cancer Res Clin Oncol Date: 2011-12-08 Impact factor: 4.553
Authors: Michael A Fischer; Bart Vrugt; Hatem Alkadhi; Dieter Hahnloser; Thomas F Hany; Patrick Veit-Haibach Journal: Eur J Nucl Med Mol Imaging Date: 2014-04-24 Impact factor: 9.236
Authors: Luis J García-Flórez; Guillermo Gómez-Álvarez; Ana M Frunza; Luis Barneo-Serra; Manuel F Fresno-Forcelledo Journal: World J Gastrointest Surg Date: 2015-09-27
Authors: Ane L Appelt; Ivan R Vogelius; John Pløen; Søren R Rafaelsen; Jan Lindebjerg; Birgitte M Havelund; Søren M Bentzen; Anders Jakobsen Journal: Int J Radiat Oncol Biol Phys Date: 2014-07-08 Impact factor: 7.038
Authors: Atthaphorn Trakarnsanga; Mithat Gönen; Jinru Shia; Garrett M Nash; Larissa K Temple; José G Guillem; Philip B Paty; Karyn A Goodman; Abraham Wu; Marc Gollub; Neil Segal; Leonard Saltz; Julio Garcia-Aguilar; Martin R Weiser Journal: J Natl Cancer Inst Date: 2014-09-22 Impact factor: 13.506